P-glycoprotein (Abcb1) is involved in absorptive drug transport in skin.

The purpose of the present study was to investigate the role of P-glycoprotein (P-gp) in drug disposition in skin. The distribution of P-gp substrates (rhodamine 123 and itraconazole) to the skin after administration from the epidermal side was lower in P-gp gene knockout (mdr1a/1b(-/-)) mice than that in wild-type mice. Coadministration of propranolol, a P-gp inhibitor, decreased the distribution of itraconazole to the skin in wild-type mice, but not in mdr1a/1b(-/-) mice. These results suggest that P-gp contributes to the influx (from the epidermal side) of its substrates into skin, although P-gp is generally involved in efflux of drugs from various tissues. This finding was supported by the lower vectorial transport of rhodamine 123 from the epidermal to the hypodermal side in mdr1a/1b(-/-) mice in Ussing-type chamber experiments and by the immunohistochemical localization of P-gp throughout the dermal layer. Distribution of itraconazole after intravenous administration, on the other hand, was higher in mdr1a/1b(-/-) mice than that in wild-type mice, suggesting that P-gp transports this drug from the skin to the circulation. The present findings are the first to demonstrate involvement of P-gp in dermal drug disposition.

[1]  L. Bolund,et al.  Side population cells in human and mouse epidermis lack stem cell characteristics. , 2004, Experimental cell research.

[2]  T. Tsuruo,et al.  P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. , 1992, Life sciences.

[3]  Y. Kato,et al.  Organic Cation/Carnitine Transporter OCTN2 (Slc22a5) Is Responsible for Carnitine Transport across Apical Membranes of Small Intestinal Epithelial Cells in Mouse , 2006, Molecular Pharmacology.

[4]  Y. Kato,et al.  Involvement of organic anion transport system in transdermal absorption of flurbiprofen. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Thierry Buclin,et al.  Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance , 2004, Clinical pharmacology and therapeutics.

[6]  C. Harding The stratum corneum: structure and function in health and disease , 2004, Dermatologic therapy.

[7]  J. Heykants,et al.  Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography. , 1987, Journal of chromatography.

[8]  J. H. Beijnen,et al.  Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.

[9]  M. Fromm,et al.  Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. , 2006, Fundamental & clinical pharmacology.

[10]  J. Watson,et al.  Neonatal murine epidermal cells express a functional multidrug-resistant pump. , 2000, The Journal of investigative dermatology.

[11]  T. Tsuruo,et al.  P-Glycoprotein-Mediated Transport of Itraconazole across the Blood-Brain Barrier , 1998, Antimicrobial Agents and Chemotherapy.

[12]  N. Jain,et al.  Liquid crystalline pharmacogel based enhanced transdermal delivery of propranolol hydrochloride. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[13]  B. W. Barry,et al.  Novel mechanisms and devices to enable successful transdermal drug delivery. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[14]  R. Shanks,et al.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update. , 1987, Clinical pharmacokinetics.

[15]  E. Schuetz,et al.  Interaction of Cytochrome P450 3A Inhibitors with P-Glycoprotein , 2002, Journal of Pharmacology and Experimental Therapeutics.

[16]  T. Hasegawa,et al.  Effect of Endotoxin on P-Glycoprotein-Mediated Biliary and Renal Excretion of Rhodamine-123 in Rats , 2001, Antimicrobial Agents and Chemotherapy.

[17]  Y. Chardonnet,et al.  Active cell membrane mechanisms involved in the exclusion of RH 123 allow distinction between normal and tumoral cells , 1994, Cell Biology and Toxicology.

[18]  T. Terasaki,et al.  Physiologically Based Pharmacokinetic Model for β-Lactam Antibiotics I: Tissue Distribution and Elimanation Rates , 1983 .

[19]  Y. Tokura,et al.  Quinolone photoallergy: photosensitivity dermatitis induced by systemic administration of photohaptenic drugs. , 1998, Journal of dermatological science.

[20]  Y. Kato,et al.  Characterization of the transdermal transport of flurbiprofen and indomethacin. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[21]  Y. Sai,et al.  Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P‐glycoprotein , 2001, The Journal of pharmacy and pharmacology.

[22]  R. Shanks,et al.  Clinical Pharmacokinetics of β-Adrenoceptor Antagonists , 1987 .

[23]  R. Agarwal,et al.  Multiple cytochrome P450 isozymes in murine skin: induction of P450 1A, 2B, 2E, and 3A by dexamethasone. , 1994, The Journal of investigative dermatology.

[24]  F. Lammert,et al.  Active influx transport is mediated by members of the organic anion transporting polypeptide family in human epidermal keratinocytes. , 2003, The Journal of investigative dermatology.

[25]  T. Nabeshima,et al.  Intracutaneous Distributions of Fluconazole, Itraconazole, and Griseofulvin in Guinea Pigs and Binding to Human Stratum Corneum , 2004, Antimicrobial Agents and Chemotherapy.

[26]  S. Frankenberg,et al.  Expression of multiple cytochrome p450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. , 2001, The Journal of investigative dermatology.

[27]  G. Mundy,et al.  Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations , 2006, Osteoporosis International.

[28]  Jörg Huwyler,et al.  Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. , 2003, Journal of medicinal chemistry.

[29]  M. Nap,et al.  Immunohistochemical detection of P-glycoprotein on frozen and paraffin-embedded tissue sections of normal and malignant tissues. , 1995, Anticancer research.

[30]  D. Stevens,et al.  Effect of cyclodextrin on the pharmacology of antifungal oral azoles , 1992, Antimicrobial Agents and Chemotherapy.

[31]  J. Heykants,et al.  Determination of cisapride in plasma and animal tissues by high-performance liquid chromatography. , 1988, Journal of chromatography.

[32]  Y. Sai,et al.  Active Secretion of Drugs from the Small Intestinal Epithelium in Rats by P‐Glycoprotein Functioning as an Absorption Barrier , 1996, The Journal of pharmacy and pharmacology.

[33]  Groen,et al.  Itraconazole pulse therapy is effective in the treatment of Majocchi's granuloma: a clinical and pharmacokinetic evaluation and implications for possible effectiveness in tinea capitis , 1998, Clinical and experimental dermatology.

[34]  A. Tsuji Transporter-mediated Drug Interactions. , 2002, Drug metabolism and pharmacokinetics.

[35]  D. Balayssac,et al.  Does inhibition of P-glycoprotein lead to drug-drug interactions? , 2005, Toxicology letters.

[36]  M. Waterman,et al.  A Keratinocyte-specific Epoxygenase, CYP2B12, Metabolizes Arachidonic Acid with Unusual Selectivity, Producing a Single Major Epoxyeicosatrienoic Acid* , 1998, The Journal of Biological Chemistry.

[37]  T. Terasaki,et al.  Physiologically based pharmacokinetic model for cefazolin in rabbits and its preliminary extrapolation to man. , 1985, Drug metabolism and disposition: the biological fate of chemicals.

[38]  P. Borst,et al.  Mammalian ABC transporters in health and disease. , 2002, Annual review of biochemistry.

[39]  M. Waterman,et al.  Differentiating Keratinocytes Express a Novel Cytochrome P450 Enzyme, CYP2B19, Having Arachidonate Monooxygenase Activity* , 1998, The Journal of Biological Chemistry.

[40]  T. Imai,et al.  Multidrug Resistance—Associated Protein 1 Functions as an Efflux Pump of Xenobiotics in the Skin , 2005, Pharmaceutical Research.

[41]  T. Terasaki,et al.  Physiologically based pharmacokinetic model for beta-lactam antibiotics I: Tissue distribution and elimination in rats. , 1983, Journal of pharmaceutical sciences.

[42]  L. Benet,et al.  Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. , 2004, International journal of pharmaceutics.